Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.

• Status: Completed
• Trial end date: 2017-01-03

Summary

An open-label, multicenter, phase I/II clinical trial to identify the [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) dose with most favorable safety prospect and confirmed ability to mitigate high-dose methotrexate induced toxicity during treatment of osteosarcoma patients

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Isofol Medical AB
• Treatments: Calcium; Leucovorin; Levoleucovorin; Methotrexate; Tetrahydrofolates